Menü
Das neue sharewise ist da Übersichtlicher, schneller, mit heller und dunkler Ansicht — und allem, was du kennst. Jetzt ausprobieren
You need to sign in or sign up before continuing.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Crown Holdings, Inc. (CCK) Soars to 52-Week High, Time to Cash Out?
Crown Holdings, Inc. (CCK) Soars to 52-Week High, Time to Cash Out?

A strong stock as of late has been Crown Holdings (CCK). Shares have been marching higher, with the stock up 8.4% over the past month. The stock hit a new 52-week high of $121.9 in the previous

Utah Medical's Q2 Earnings Down Y/Y Due to Customer LossesPhoto, wide shot, wide-angle lens,  Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

Shares of Utah Medical Products, Inc. UTMD have gained 2.6% since the company reported its earnings for the quarter ended June 30, 2026. This compares to the S&P 500 index’s 1.4% decline over the

Popular, Inc. (BPOP) Soars to 52-Week High, Time to Cash Out?
Popular, Inc. (BPOP) Soars to 52-Week High, Time to Cash Out?

Shares of Popular (BPOP) have been strong performers lately, with the stock up 4.7% over the past month. The stock hit a new 52-week high of $176.51 in the previous session. Popular has gained 40.6%

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Novo Nordisk NVO is scheduled to report its second-quarter 2026 results on Aug. 5, 2026, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is

HomeTrust Bancshares, Inc. (HTB) Soars to 52-Week High, Time to Cash Out?
HomeTrust Bancshares, Inc. (HTB) Soars to 52-Week High, Time to Cash Out?

A strong stock as of late has been HomeTrust Bancshares (HTB). Shares have been marching higher, with the stock up 3.7% over the past month. The stock hit a new 52-week high of $52.21 in the

Will Weak Property-Liability Underwriting Hurt Allstate's Q2 Earnings?Photo, wide shot, wide-angle lens, soft focus,  Risk management company, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-vkrXsXVXnZepYEkiT4BvjtCA.png?st=2023-05-14T13%3A27%3A43Z&se=2023-05-14T15%3A27%3A43Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-14T00%3A09%3A01Z&ske=2023-05-15T00%3A09%3A01Z&sks=b&skv=2021-08-06&sig=y1VhH4rrtYGKSVOHO3rBwhpmvE42GCwp7%2BKdLaLI7kA%3D
Will Weak Property-Liability Underwriting Hurt Allstate's Q2 Earnings?

Insurance provider The Allstate Corporation ALL is set to report its second-quarter 2026 results on Aug. 5, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s

Should You Buy, Sell or Hold Lemonade Stock Post Q2 Earnings?
Should You Buy, Sell or Hold Lemonade Stock Post Q2 Earnings?

Lemonade Inc. LMND posted decent second-quarter 2026 results, with both the top and bottom lines improving year over year. Though the top line beat the Zacks Consensus Estimate, the bottom line

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?Photo, wide shot, wide-angle lens,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity

Should You Invest in the ALPS Electrification Infrastructure ETF (ELFY)?Photo, wide shot, wide-angle lens,  Gas company, Midday, harsh overhead sunlight, directional sunlightt, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/07ff6859-914a-4fdd-8473-abdbac8978f6.png
Should You Invest in the ALPS Electrification Infrastructure ETF (ELFY)?

Designed to provide broad exposure to the Utilities - Infrastructure segment of the equity market, the ALPS Electrification Infrastructure ETF (ELFY) is a passively managed exchange traded fund

Avino Silver (ASM) Q2 Earnings Preview: What's in the Cards?Photo, wide shot, wide-angle lens,  Gold mine, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/94faf2bd-99c1-4ea6-b55d-fdcab23c3865.png
Avino Silver (ASM) Q2 Earnings Preview: What's in the Cards?

The market expects Avino Silver (ASM) to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended June 2026. This widely-known

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre Therapeutics SYRE incurred a loss of 36 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 71 cents. In the year-ago quarter, the company

Should You Invest in the Invesco S&P Global Water Index ETF (CGW)?
Should You Invest in the Invesco S&P Global Water Index ETF (CGW)?

The Invesco S&P Global Water Index ETF (CGW) was launched on May 14, 2007, and is a passively managed exchange traded fund designed to offer broad exposure to the Industrials - Water segment of the

Should You Invest in the Invesco S&P 500 Equal Weight Industrials ETF (RSPN)?
Should You Invest in the Invesco S&P 500 Equal Weight Industrials ETF (RSPN)?

Designed to provide broad exposure to the Industrials - Broad segment of the equity market, the Invesco S&P 500 Equal Weight Industrials ETF (RSPN) is a passively managed exchange traded fund

TripAdvisor Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Hotel, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/d14bb504-852b-4d13-a69a-8cec9d4eb799.png
TripAdvisor Q2 Earnings Call Highlights

Key Points

Should You Invest in the Global X U.S. Electrification ETF (ZAP)?
Should You Invest in the Global X U.S. Electrification ETF (ZAP)?

Designed to provide broad exposure to the Energy - Broad segment of the equity market, the Global X U.S. Electrification ETF (ZAP) is a passively managed exchange traded fund launched on December

Should Inspire 500 ETF (PTL) Be on Your Investing Radar?
Should Inspire 500 ETF (PTL) Be on Your Investing Radar?

Designed to provide broad exposure to the Large Cap Blend segment of the US equity market, the Inspire 500 ETF (PTL) is a passively managed exchange traded fund launched on March 25, 2024.

The fund

CRWV Stock Ahead of Q2 Earnings: Buy, Sell, or Wait for the Results?
CRWV Stock Ahead of Q2 Earnings: Buy, Sell, or Wait for the Results?

CoreWeave, Inc. CRWV is scheduled to report second-quarter 2026 results on Aug. 11, 2026, after market close.

The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged

5 Stocks With Recent Price Strength to Tap August Rally
5 Stocks With Recent Price Strength to Tap August Rally

U.S. stock markets returned to a northward journey after a mixed June and July. In the first week of August, the Dow, the S&P 500 and the Nasdaq Composite rallied 3%, 3.6% and 5.2%, respectively

LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out?
LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out?

A strong stock as of late has been LifeStance Health Group (LFST). Shares have been marching higher, with the stock up 9.4% over the past month. The stock hit a new 52-week high of $12.43 in the

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?Photo, wide shot, wide-angle lens,  Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the